nach oben

Reactions Weekly

Erschienen in:

01.06.2019 | Case report

Lenvatinib

Development of resistance in advanced differentiated thyroid carcinoma: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Sheu N-W, et al. Lenvatinib complementary with radioiodine therapy for patients with advanced differentiated thyroid carcinoma: Case reports and literature review. World Journal of Surgical Oncology 17: 84, No. 1, 19 May 2019. Available from: URL: http://doi.org/10.1186/s12957-019-1626-4 - Taiwan

Titel: Lenvatinib
Development of resistance in advanced differentiated thyroid carcinoma: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-64052-z

Springer Medizin

Lenvatinib

Development of resistance in advanced differentiated thyroid carcinoma: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Multiple drugs

Decitabine

Rosuvastatin

Antithrombin-III/thrombomodulin-α

Prednisolone

Trastuzumab

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Multiple drugs

Decitabine

Rosuvastatin

Antithrombin-III/thrombomodulin-α

Prednisolone

Trastuzumab